Alnylam Pharmaceuticals
ALNY
376 hedge funds and large institutions have $14B invested in Alnylam Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 124 increasing their positions, 127 reducing their positions, and 36 closing their positions.
61% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 36
5% more funds holding
Funds holding: 357 → 376 (+19)
9% more call options, than puts
Call options by funds: $133M | Put options by funds: $123M
0.56% less ownership
Funds ownership: 93.54% → 92.99% (-0.56%)
2% less repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 127
11% less capital invested
Capital invested by funds: $15.8B → $14B (-$1.75B)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$64.3M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$40.2M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$32.2M |
| 4 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$26.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$24.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$113M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$58.7M |
| 3 |
DFO
Duquesne Family Office
New York
|
-$53.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$50.3M |
| 5 |
SPC
Slate Path Capital
New York
|
-$31M |
ALNY Hedge Fund Activity: Q4 2020 in Review
376 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2020, worth a combined $14B — down 11% from $15.8B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new ALNY positions and 36 closed out — a net gain of 22 holders — while 124 added to existing stakes and 127 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $64.3M. The largest seller was Farallon Capital Management, cutting an estimated $113M.
- 376 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2020, up from 357 in Q3 2020.
- Funds reported $14B of Alnylam Pharmaceuticals stock for Q4 2020, down 11% quarter-over-quarter.
- 58 funds opened new Alnylam Pharmaceuticals positions in Q4 2020 and 36 closed out, a net change of +22 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2020 was Point72 Asset Management, an estimated $64.3M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2020 was Farallon Capital Management, an estimated $113M sold.
Based on aggregated 13F filings for Q4 2020.